Vol 51(2017) N 6 p. 772-781; DOI 10.1134/S0026893317060097
Engineering Antibodies as Drugs: Principles and PracticeMorphic Therapeutic, Waltham, MA 02451 USA
Received - 2017-05-13; Accepted - 2017-05-22
Over the last forty years, recombinant antibodies have been transformed from an unproven experimental approach to a therapeutic modality with multiple success stories in the treatment of cancer, inflammation, infections and cardiometabolic diseases. Owing to their high affinity and selectivity for the target antigen, their multimodal tunable mode of action, their modular nature and long half-life, antibodies now hold prominent positions in the pipelines of major biopharmaceutical companies. In this brief report, I aim to highlight the themes that have shaped the therapeutic antibody engineering as it exists today and to offer a personal perspective on its future developments. Distinct antibody engineering history, developments and trends in Russian Federation will not be discussed since they are detailed elsewhere in this journal issue.
Antibody, antibody engineering, antibody-drug conjugates, immunooncology, effector function, multispecific antibodies and mixtures